The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
- PMID: 27207350
- DOI: 10.1177/1203475416651605
The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
Abstract
Background: Major advances have been made in the understanding of the pathophysiology of psoriasis.
Objectives: The authors review the role of interleukin (IL) 17 in the pathogenesis of psoriasis and provide updates on approved and investigational therapies targeting IL-17 and the IL-17 receptor.
Methods: A PubMed search was performed for relevant literature.
Conclusion: The IL-23/Th17 signaling pathway (including IL-17) plays a central role in the pathogenesis of psoriasis. Biologic agents that block IL-17 (secukinumab and ixekizumab) or its receptor (brodalumab) are effective and safe for the treatment of psoriasis.
Keywords: IL-17; brodalumab; ixekizumab; psoriasis; secukinumab.
© The Author(s) 2016.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical